Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study

Table 1 Demographic and disease-related baseline characteristics (mean ± SD)

	Placebo (n = 25)	LCR35 (n = 25)
Sex, n (%)
Male	5 (20.0)	10 (40.0)
Female	20 (80.0)	15 (60.0)
Age (yr)	48.0 ± 10.8	46.1 ± 11.3
Height (cm)	163.2 ± 7.6	168.2 ± 7.6
Weight (kg)	65.5 ± 13.1	66.4 ± 14.9
BMI (kg/m²)	24.5 ± 4.0	23.4 ± 4.9
IBS severity score	247.1 ± 43.8	261.5 ± 39.4
Abdominal pain score	36.7 ± 20.6	44.6 ± 13.2
GIQLI	62.9 ± 8.6	63.9 ± 7.8
HAD score	16.5 ± 6.4	16.3 ± 6.5
IBS subgroups
IBS with predominance of constipation, n (%)	7 (28.0)	4 (16.0)
IBS severity score	270.4 ± 28.4	281.5 ± 9.9
IBS with predominance of diarrhoea	8 (32.0)	7 (28.0)
IBS severity score	259.6 ± 53.7	286.1 ± 11.2
Abdominal pain score	36.6 ± 27.2	51.4 ± 12.4
Mixed IBS, n (%)	6 (24.0)	11 (44.0)
IBS severity score	222.3 ± 36.7	245.0 ± 42.0
Unsubtyped IBS, n (%)	4 (16.0)	3 (12.0)
IBS severity score	218.5 ± 27.1	238.0 ± 63.6

NB: No statistical difference was found between the groups; BMI: Body mass index; IBS: Irritable bowel syndrome; GIQLI: Gastrointestinal quality of life index; HAD: Hospital anxiety and depression.